Recent evidence has indicated that cathepsin D (CTSD), a lysosomal enzyme, is a key player in developing hepatic inflammation and dyslipidemia and is a marker for NASH (Houben et al., 2017). Here, CTSD is linked to metabolic dysfunction-associated steatohepatitis.